JP2025513851A5 - - Google Patents
Info
- Publication number
- JP2025513851A5 JP2025513851A5 JP2024560405A JP2024560405A JP2025513851A5 JP 2025513851 A5 JP2025513851 A5 JP 2025513851A5 JP 2024560405 A JP2024560405 A JP 2024560405A JP 2024560405 A JP2024560405 A JP 2024560405A JP 2025513851 A5 JP2025513851 A5 JP 2025513851A5
- Authority
- JP
- Japan
- Prior art keywords
- capsid
- pharmaceutical composition
- aav
- viral vector
- itr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330245P | 2022-04-12 | 2022-04-12 | |
| US63/330,245 | 2022-04-12 | ||
| PCT/US2023/065689 WO2023201274A1 (en) | 2022-04-12 | 2023-04-12 | Use of an irak4 modulator for gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513851A JP2025513851A (ja) | 2025-04-30 |
| JP2025513851A5 true JP2025513851A5 (enExample) | 2026-04-20 |
Family
ID=86329943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560405A Pending JP2025513851A (ja) | 2022-04-12 | 2023-04-12 | 遺伝子治療のためのｉｒａｋ４モジュレーターの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405014A1 (enExample) |
| EP (1) | EP4508226A1 (enExample) |
| JP (1) | JP2025513851A (enExample) |
| KR (1) | KR20250004738A (enExample) |
| CN (1) | CN119343458A (enExample) |
| AU (1) | AU2023253700A1 (enExample) |
| CA (1) | CA3248216A1 (enExample) |
| IL (1) | IL316222A (enExample) |
| MX (1) | MX2024012617A (enExample) |
| TW (1) | TW202402329A (enExample) |
| WO (1) | WO2023201274A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| AU2024406222A1 (en) | 2023-12-20 | 2026-06-04 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| WO2025158385A1 (en) * | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 |
| JP5956331B2 (ja) | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えａａｖベクターの改良された精製方法 |
| US20110070241A1 (en) * | 2009-06-30 | 2011-03-24 | Duke University | Methods for modulating immune responses to aav gene therapy vectors |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020264490A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| EP4149622A4 (en) * | 2020-05-12 | 2024-12-18 | Myogene Bio LLC | IMMUNOSUPPRESSIVE AGENTS AND METHODS OF RE-DOSING VIRAL ADMINISTRATION FOR GENE THERAPY |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
-
2023
- 2023-04-12 JP JP2024560405A patent/JP2025513851A/ja active Pending
- 2023-04-12 EP EP23722240.1A patent/EP4508226A1/en active Pending
- 2023-04-12 CA CA3248216A patent/CA3248216A1/en active Pending
- 2023-04-12 AU AU2023253700A patent/AU2023253700A1/en active Pending
- 2023-04-12 CN CN202380044027.8A patent/CN119343458A/zh active Pending
- 2023-04-12 WO PCT/US2023/065689 patent/WO2023201274A1/en not_active Ceased
- 2023-04-12 KR KR1020247037272A patent/KR20250004738A/ko active Pending
- 2023-04-12 TW TW112113696A patent/TW202402329A/zh unknown
- 2023-04-12 US US18/299,640 patent/US20230405014A1/en active Pending
- 2023-04-12 IL IL316222A patent/IL316222A/en unknown
-
2024
- 2024-10-10 MX MX2024012617A patent/MX2024012617A/es unknown